Bovine respiratory diseases consist of two types, alveolar pneumonia and interstitial pneumonia \[[@r1]\]. Pneumonia caused by bacterial and mycoplasma infection is mainly of the alveolar type \[[@r1]\]. Enrofloxacin (ERFX), one of the fluoroquinolones, has a broad spectrum of antimicrobial activity *in vitro* against the pathogens commonly associated with bovine respiratory diseases \[[@r7],[@r8],[@r9]\]. In order to treat alveolar pneumonia effectively with ERFX, it is necessary that administered ERFX reaches the intrapulmonary area and that the ERFX concentration achieves higher than the minimum inhibitory concentration (MIC) for target pathogenic microbes \[[@r5], [@r7],[@r8],[@r9], [@r10]\]. However, ERFX has been used for treatment of bovine respiratory diseases without knowledge about the intrapulmonary distribution in calves. Therefore, it is necessary to elucidate the distribution of ERFX in the intrapulmonary area in calves.

The purpose of this study was to elucidate the concentration of ERFX in bronchoalveolar lavage fluid (BALF) after administration in healthy calves.

Four 2-week-old clinically healthy Holstein bull calves with body weights of 50.6 ± 3.9 kg (mean ± SD) were used in this study. The animals were cared for according to the Guide for the Care and Use of Laboratory Animals of the Joint Faculty of Veterinary Medicine, Kagoshima University.

A single dose (5 mg/kg) of commercial ERFX (Baytril 5% injectable solution, Bayer, Tokyo, Japan) was administered to all calves by subcutaneous injection. Collection of body temperature, heart rate, respiratory rate and visual inspection data was conducted at 0 (before administration), 1, 2 and 3 hr after administration. In addition, peripheral blood samples were collected at 0 (before administration), 1, 2 and 3 hr after administration via the jugular vein using heparinized tubes (VP-H050K, Terumo, Tokyo, Japan) and Vacutainer tubes (VP-NA052K, Terumo) containing dispotassium ethylenediaminetetraacetic acid (EDTA-2AK). This examination was conducted two times, one week apart.

Blood collected into tubes with EDTA-2AK was used for counting of white blood cells (WBCs) and red blood cells (RBCs) and hemoglobin (Hb) and hematocrit (Ht) analysis by automated cell counter (Poch-100iv, Sysmex, Kobe, Japan) within 1 hr after collection.

Plasma was separated from blood collected into heparinized tubes by centrifugation and stored at −70°C until analysis. BALF was collected at 0 (before administration), 1 and 2 hr after administration of ERFX using a flexible electronic endoscope (VQ TYPE 5112B, Olympus, Tokyo, Japan). The upper airway of subjects was prepared for bronchoscopy by application of 2% lidocaine. The flexible electronic endoscope was inserted into a subsegment of each lobe. Two 50-m*l* aliquots of sterile 0.9% normal saline solution were instilled into the lobe and immediately aspirated. The second aspiration was pooled with the first one. The volume of BALF was measured and recorded. BALF was collected from the left and right lobes in three places each, for a total of six places in the lung (right middle lobe, third bronchiole of the right caudal lobe, fifth bronchiole of the right caudal lobe, second bronchiole of the left caudal lobe, third bronchiole of the left caudal lobe and fifth bronchiole of the left caudal lobe). The BALF was immediately sent to a laboratory for cell counting, and then, 1.5 m*l* of BALF was centrifuged at 400 *g* for 5 min. The supernatant and cell pellets were separated and frozen at −70°C until assays. All calves were used again after one week for the same procedure. The concentration of ERFX was measured by the high-performance liquid chromatography with tandem mass spectrometry (LC/MS/MS) method based on the previously established procedure reported by De Baere *et al.* \[[@r2]\]. Plasma samples (100 *µl*) were diluted 10 times with distilled water. Each BALF cell pellet sample was mixed with 0.5 m*l* of 1 mol sodium hydroxide to lyse cells and then mixed with 1.0 m*l* of 3% formic acid. Three hundred microliters of each sample (diluted plasma, supernatant of BALF and lysed BALF cell pellet) was mixed with 60 *µl* of internal standard (Lomefloxacin, Sigma-Aldrich, Tokyo, Japan; 300 *n*g/m*l* in 1% formic acid/methanol (4:1)) and 60 *µl* of methanol. The samples (350 *µl*) were loaded into a solid-phase extraction column (Oasis HLB, Waters, Tokyo, Japan). The residue was dissolved in 250 *µl* of mobile phase. An aliquot (10 *µl*) of the extract was injected into the LC/MS/MS (Prominence, Shimadzu, Kyoto, Japan; 4000 QTRAP, AB, Sciex, Tokyo, Japan). The average recovery rate was 81.5% for ERFX. The reproducibility was 1.6% for ERFX.

The ERFX concentration was determined in pulmonary epithelial lining fluid (ELF) and alveolar cells in BALF \[[@r4], [@r5]\]. The concentration of ERFX in ELF (ERFX~ELF~) was determined as follows:
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where *ERFX~BALF~* was the concentration of ERFX in BALF, ***urea****~Plasma~* is the concentration of urea in plasma, and ***urea****~BALF~* is the concentration of urea in BALF.

The concentration of ERFX in alveolar cells (ERFX~AC~) was determined as follows:
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where *AC~PELLET~* was the concentration of ERFX in the alveolar cell pellet and *V~AC~* was the mean volume of cattle BALF cells. A volume of 1.28 *µl*/10^6^ BALF cells, devised in another bovine study, was used for the volume of BALF cells \[[@r4], [@r5]\].

Data are shown as the total values of the first and second examinations. Statistical analyses of data were conducted using analysis of variance (one-way ANOVA) followed by the Tukey--Kramer multiple comparison test to determine the difference in ERFX within the same sampling times. All statistical analyses were performed using the IBM SPSS Statistics 21 software (IBM, Tokyo, Japan), and *P*\<0.05 was considered statistically significant.

The body temperature, heart rates and respiratory rates of the calves hardly fluctuated, and abnormal clinical findings were not recognized by visual inspection during the experiment. The WBC, RBC, Hb and Ht values of the calves hardly fluctuated during the experiment. The mean ERFX concentrations in plasma at 1 and 2 hr after administration were 1.23 *µ*g/m*l* and 1.29 *µ*g/m*l,* respectively ([Table 1](#tbl_001){ref-type="table"}Table 1.Concentration of enrofloxacin in plasma, pulmonary epithelial lining fluid and alveolar cells at 0, 1 and 2 hr after administration of enrofloxacin0 hr1 hr2 hrEnrofloxacin in plasma(*µ*g/m*l*)N.D.1.23 ± 0.22^a,b)^1.29 ± 0.10^d,e)^Enrofloxacin in pulmonary epithelial lining fluid(*µ*g/m*l*)N.D.8.53 ± 2.48^a,c)^9.42 ± 3.41^d,f)^Enrofloxacin in alveolar cells(*µ*g/m*l*)N.D.4.04 ± 1.62^b,c)^5.19 ± 2.22^e,f)^Data are shown as the mean ± SD, N.D.: not detected. Value indicated with the same letters are significant different within the same sampling time (a--f: *P*\<0.01).). The mean ERFX concentrations in ELF at 1 and 2 hr after administration were 8.53 *µ*g/m*l* and 9.42 *µ*g/m*l*, respectively, and the mean ERFX concentration in alveolar cells were 4.04 *µ*g/m*l* and 5.19 *µ*g/m*l*. The mean ERFX concentrations in ELF and alveolar cells at 1 and 2 hr were significantly higher than those in plasma (*P*\<0.01).

The distribution of ERFX to the intrapulmonary area in dogs and horses has been reported \[[@r6], [@r12]\]. In calves, the distribution of ERFX to plasma or serum after a single subcutaneous administration has been elucidated \[[@r3], [@r11]\], however, the distribution of ERFX to the intrapulmonary area has not been determined. Therefore, the aim of this study was to elucidate the distribution of ERFX to ELF and alveolar cells after a single subcutaneous administration of ERFX at 5 mg/kg to calves. We confirmed that ERFX was distributed into the ELF and alveolar cells in BALF at 1 and 2 hr after administration. The ERFX concentrations in ELF and alveolar cells, which were above 4 *µ*g/m*l*, were higher than those in plasma concentrations. Previous studies reported that the MIC~90~ values of EFRX for *Pasteurella multocida*, *Mannheimia haemolytica* and *Mycoplasma bovis* were 0.31 *µ*g/m*l*, 0.50 *µ*g/m*l* and 1.56 *µ*g/m*l*, respectively \[[@r7],[@r8],[@r9]\]. Although the data in the present study were obtained only at 1 and 2 hr after subcutaneous administration, ERFX might be an effective antibacterial agent for pathogenic bacteria and mycoplasma intracellularly as well as extracellularly in the intrapulmonary area, judging from the high concentrations found in ELF and alveolar cells.

In the present study, the body temperature, heart rates and respiratory rates in calves did not fluctuate, and abnormal clinical findings were not recognized by visual inspection at before or after BALF collection. Therefore, BALF collection might be a safe and useful method in calves.

Further studies with continuous administration and long-term administration are needed to clarify distribution of ERFX to the intrapulmonary area after subcutaneous administration in calves.
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